Stock APLS APELLIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Market Closed - Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
35.41 USD +1.23% Intraday chart for Apellis Pharmaceuticals, Inc. -12.42% -40.85%
Jun. 28 Sector Update: Health Care Stocks Edge Higher in Afternoon Trading MT
Jun. 28 Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $49 From $52, Maintains Neutral Rating MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
GL
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
GL
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
GL
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
GL
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
GL
Apellis Pharmaceuticals : First Quarter 2024 Earnings Presentation
PU
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
GL
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
GL
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
GL
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
GL
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
GL
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
GL
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
GL
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
AQ
Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APLS Stock
  4. News Apellis Pharmaceuticals, Inc.
  5. Press Releases